Adverse drug reactions are common both in outpatient and inpatient settings. A meta-analysis of 39 prospective studies from American hospitals that was published in 1998 reported an incidence of serious adverse drug reactions of 6.7% and fatal adverse drug reactions of 0.32%, which places these reactions around the fourth to sixth leading causes of death in the United States. A review published in 2005 found that adverse drug reactions affected 10%–20% of patients admitted to hospital and more than 7% of the general population.

Health Canada has documented an increase in reported adverse drug reactions, with nearly 30,000 reports of adverse drug reactions in 2009 (up 35% from the year before). In addition, adverse drug reactions are more common among older patients. The Canadian Institute for Health Information (CIHI) reported that patients 65 years or older accounted for 57.6% of hospital admissions related to adverse drug reactions in Canada between 2006/07 and 2011/12, even though they accounted for only 14.2% of the Canadian population.

Adverse drug reactions are defined by the World Health Organization (WHO) as, “all intended pharmacologic effects of a drug except therapeutic failures, intentional over-dosage, abuse of the drug, or errors in administration.” The WHO defines adverse drug events as “an injury resulting from medical intervention related to a drug,” which, in contrast to adverse drug reactions, also includes in its definition errors in medication use, such as overdose.

In this review, we focus on allergic drug reactions and address key issues in diagnosis and management. The articles referenced in this review include guidelines, cohort and case-control studies, and surveys (Box 1).

How are adverse drug reactions classified?

Adverse drug reactions can be classified into predictable (“type A”) and unpredictable (“type B”) reactions. Predictable reactions account for 80% of all adverse drug reactions; they are common, dose-dependent and caused by the pharmacologic actions of the drug. In contrast, unpredictable reactions are uncommon, independent of dose and unrelated to pharmacologic effects of the drug (Table 1). Allergic drug reactions account for about 5%–10% of adverse drug reactions overall. Although the term “drug allergy” has often been used exclusively for immunoglobulin E (IgE)-mediated reactions, more recently, an expert panel on drug allergy discussed whether or not the term drug allergy should also include other forms of hypersensitivity reactions that are not IgE mediated.

What are the clinical manifestations of allergic drug reactions?

Although allergic reactions to medications can affect any organ system, cutaneous manifestations are by far the most common. A 2017 meta-analysis and systematic review of 53 studies (126,306 participants) found cutaneous manifestations to be present in 68.2% of adverse drug reactions (with anaphylactic or systemic reactions in 10.8%). Determining the characteristics of the cutaneous manifestation, if present, is one of the strongest diagnostic clues in a drug-induced allergic reaction.

A 2016 review on cutaneous allergic drug reactions noted that most of these eruptions are benign in nature. The most common
cutaneous eruption is a generalized maculopapular exanthem, which accounts for up to 90% of all cutaneous eruptions caused by drugs. The most severe reactions are Stevens–Johnson syndrome and toxic epidermal necrolysis. Table 2 describes clinical features of the more common types of allergic drug reactions.

### How is drug allergy diagnosed?

#### History

The approach to diagnosis begins with the patient’s medical history, which may identify the etiology of the reaction, identify drug allergy as a possible cause of symptoms and provide details.

### Table 1: Classification of unpredictable adverse drug reactions

| Classification | Description | Example |
|----------------|-------------|---------|
| Intolerance    | Occurs at very low doses and is not due to underlying abnormalities of metabolism, bioavailability or excretion | ASA-induced tinnitus |
| Idiosyncracy   | Unrelated to intended pharmacologic action of the drug, is reproducible, and is usually due to abnormalities of metabolism, excretion or bioavailability | Primaquine-induced hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency |
| Allergy        | Immune mediated: Type 1 (IgE-mediated) Type 2 (cytotoxic) Type 3 (immune complex) Type 4 (delayed hypersensitivity; subclassified into monocytes (IVa), eosinophils (IVb), CD8+ T lymphocytes (IVc), neutrophils (IVd) | Type 1: anaphylaxis Type 2: thrombocytopenia, anemia Type 3: serum sickness, vasculitis Type 4: benign drug exanthems, DRESS, AGEP, contact dermatitis |
| “Pseudoallergy”| Similar to type I allergic reactions with different pathophysiology (direct mediator release, often histamine, from mast cells and basophils) | Opiate-induced urticaria |

Note: AGEP = acute generalized exanthematous pustulosis, ASA = acetylsalicylic acid, DRESS = drug reaction with eosinophilia and systemic symptoms, IgE = immunoglobulin E.

### Table 2: Clinical features of drug hypersensitivity reactions

| Reaction                | Clinical manifestations |
|-------------------------|-------------------------|
| Delayed drug exanthem   | Fine macules and papules that occur days after drug initiation and resolve a few days after discontinuing the medication; lack of other systemic symptoms |
| IgE-mediated            | Combination of urticaria, angioedema, vomiting, diarrhea, cough, wheeze, hypotension and/or syncope one to six hours after starting a medication; usually requires prior sensitization |
| Serum sickness-like reaction | Rash (usually urticarial), fever, arthralgias, lymphadenopathy one to three weeks after starting a medication; could be earlier with sensitization |
| SJS/TEN                 | Mucosal involvement, fever, cutaneous target and bullous lesions (SJS: < 10% epidermal detachment; SJS/TEN overlap: 10%–30% epidermal detachment; TEN: > 30% epidermal detachment); possible involvement of liver, kidney, lungs |
| DRESS                   | Fever, eosinophilia, lymphadenopathy, liver dysfunction, possible renal dysfunction, multiple different cutaneous eruptions possible; starts up to 12 weeks after starting a medication and may persist for weeks or months after stopping the medication (Figure 1) |
| Allergic contact dermatitis | Dermatitis in area of cutaneous contact that evolves over days; requires prior sensitization (Figure 2) |
| Drug-induced lupus erythematosus | Cutaneous: photodistributed erythematous plaques Systemic: sudden onset myalgias, fever, arthralgias, malaise several weeks after drug initiation |
| Fixed drug eruption      | Hyperpigmented plaques that recur at the same site (Figure 3) |
| Other                    | Hematologic (cytopenia), hepatic (hepatitis, cholestatic jaundice), renal (interstitial nephritis), pulmonary (pneumonitis, fibrosis), vasculitis |

Note: DRESS = drug reaction with eosinophilia and systemic symptoms, IgE = immunoglobulin E, SJS = Stevens–Johnson syndrome, TEN= toxic epidermal necrolysis.
suggesting the possible type of drug-induced allergic reaction. Table 3 provides a list of useful components of the medical history. In particular, establishing the time frame of the reaction (i.e., time of onset and its duration), the constellation of symptoms, previous exposure and underlying conditions as risk factors are essential in arriving at a diagnosis. The Naranjo Adverse Drug Reaction Probability Scale can be used, based on the patient’s history, as a validated probability scale to help determine the likelihood that the symptoms described represent an adverse drug reaction. This scale based on 10 questions is relatively simple to use and is frequently cited when reporting new drug allergic reactions in the literature, but it is not used commonly in clinical practice.

**Laboratory tests**

Laboratory investigations are supportive and not confirmatory for most allergic drug reactions. The National Institute for Health and Care Excellence recommends obtaining serum tryptase levels in the diagnosis of a potential IgE-mediated reaction, because elevated serum tryptase is relatively specific, especially if serial levels normalize, although this is based on low-quality evidence largely from observational studies. Serum eosinophilia supports a diagnosis of an IgE-mediated reaction, although the absence of eosinophilia does not exclude it.

Other laboratory investigations (e.g., liver enzymes, renal function, complete blood cell count) may determine involvement of internal organs, in particular with severe nonimmediate drug-induced allergic reactions. Testing for autoantibodies is useful if there is concern about vasculitis (antineutrophil cytoplasmic antibody) or drug-induced lupus (antihistone levels in systemic drug-induced lupus, and anti-Ro/SSA and anti-La/SSB for cutaneous drug-induced lupus).

**Skin testing**

In the diagnosis of a potential IgE-mediated reaction, validated skin testing reagents exist only for penicillin and not for any of the other low-molecular-weight drugs. Several international guidelines, including the American Academy of Allergy, Asthma and Immunology guideline, recommend skin testing (a combination of skin prick testing and then intradermal testing) with the penicillin reagents because of its high negative predictive value. This is followed by an allergist-administered oral challenge — usually of amoxicillin or penicillin in children — to prove tolerance in patients who have negative skin testing.

The risk of or reacquiring a penicillin allergy is low after negative penicillin testing. Patients have been reported to tolerate both oral doses of penicillin and, according to a recent retrospective review, repeated intravenous penicillin without immediate hypersensitivity reactions.

In vitro serum-specific IgE assays are available for some common antibiotics; however, their sensitivity and specificity are not well described or validated, although studies have found a higher specificity (90% or more) than sensitivity (29% to 68%). Some guidelines do recommend the inclusion of serum-specific IgE testing if skin testing is negative despite a convincing reaction history. The basophil activation test, which looks at in vitro basophilic stimulation with an allergen and subsequent CD63 or CD203c expression, is being reported increasingly because this test shows promise in the diagnosis of IgE-mediated drug allergy, but it is not available routinely at this time. For some nonimmediate reactions, in particular contact dermatitis, fixed drug eruption and maculopapular exanthem, skin
patch testing (i.e., placing the allergen on the back at a nonirrat-
ing concentration under an aluminum disk) has been reported. In North America, it is not used commonly in the more severe nonimmediate drug reactions, such as Stevens–Johnson syn-
drome, toxic epidermal necrolysis or drug reaction with eosino-
philia and systemic symptoms. However, in Europe, both patch
testing and delayed intradermal testing (i.e., the result is read
days later) are used for nonimmediate reactions, including severe
reactions. A recent retrospective review of patch testing that
included 260 patients who received treatment in a European der-
atology clinic found that patch testing was safe and specific,
even for severe nonimmediate reactions.

Drug challenge

In most cases of drug allergy, validated skin or laboratory tests are
not available. For patients in whom the likelihood of drug allergy is
deemed low (e.g., remote reaction, benign rash), a drug challenge
can be performed by an allergist. If the history is not indicative of
an allergy (e.g., headache), a full dose can be administered to con-
firm tolerance. In most circumstances, a graded challenge is per-
formed, with the assistance of an allergist, that often involves the
administration of two graded sub-therapeutic doses of the medi-
cation to the patient, with monitoring for an allergic reaction. A US
guideline noted that drug challenges are contraindicated if the his-
tory is consistent with a severe drug reaction, such as Stevens–
Johnson syndrome, toxic epidermal necrolysis or drug reaction
with eosinophilia and systemic symptoms.

In contrast, induction of drug tolerance (e.g., drug desensi-
tization) involves providing increasing incremental doses of the
medication to the patient over a period of hours to days,
using different procedures based on the hypothesized mech-
anism of the reaction. Induction of drug tolerance does modify
the immune response to the medication temporarily while the
patient remains on the medication. It effectively modifies the
immune response to the medication, even though there is an
underlying allergy. This procedure can be used for both IgE-
and non-IgE-mediated drug allergic reactions to a variety of
drugs, including antibiotics, chemotherapeutics and biologic
agents (e.g., penicillin, acetylsalicylic acid [ASA] and allopuri-
non), but it is not used for patients with a history of a severe
drug reaction, such as Stevens–Johnson syndrome, toxic epi-
dermal necrolysis or drug reaction with eosinophilia and sys-
temic symptoms.

### Table 3: Useful components of the medical history

| Question                                      | Answer                                                                 |
|----------------------------------------------|------------------------------------------------------------------------|
| What was the time frame of the reaction?     | Allergic reactions to medications have characteristic times of onset, with some (such as IgE-mediated reactions) occurring within a few hours after a dose, and others (such as DRESS) being delayed in onset. Most drug allergies occur within the first two weeks of taking the drug; however, there are some exceptions (such as drug-induced lupus erythematosus and DRESS). |
| What cutaneous symptoms occurred?           | Knowledge of the type of skin eruption aids in determining type of testing and prognosis (for example, urticaria is suggestive of an IgE-mediated reaction, whereas a maculopapular rash is suggestive of a type IV reaction). |
| Were any other medications being used concurrently? | It is possible that a newly prescribed medication, such as an antibiotic, is blamed for a reaction that was instead caused by another medication (such as nonsteroidal anti-inflammatory drugs). |
| Has the medication been used in the past?    | Most drug-induced allergic reactions require a period of sensitization before a reaction, although some (such as DRESS) can occur on first exposure after several weeks of use. |
| Were there any patient-specific or drug-specific risk factors for a reaction? | Drug-specific risk factors include route of administration (parenteral and cutaneous routes of administration are associated with a higher degree of sensitization than oral administration), prolonged duration of dose associated with increased risk, repetitive exposure to the medication and concurrent virus (such as Epstein–Barr virus, which causes rash 100% of the time when amoxicillin is used concurrently). Host-specific risk factors include sex (female), older age, some genetic polymorphisms (such as HLA-B5701, which increases the risk of abacavir hypersensitivity) and underlying conditions (systemic lupus erythematosus, HIV) which increase the risk of allergic reactions. |
| Has this reaction occurred before?          | Some cutaneous reactions, such as urticaria, may be due to another etiology (such as chronic urticaria), instead of a drug allergy. In addition, if the reaction has occurred in the past with a particular or related drug, this increases the likelihood of drug allergy. |
| How long ago was the reaction?              | There is a high rate of outgrowing drug-induced allergic reactions to some medications (e.g., penicillin; within 10 years after an allergic reaction, most patients will be penicillin tolerant). |

Note: DRESS = drug reaction with eosinophilia and systemic symptoms, IgE = immunoglobulin E.
the “de-labelling” of patients erroneously diagnosed with penicillin allergy,35 including one from Choosing Wisely Canada.34 and have noted that erroneous labelling is associated with broad-spectrum antibiotic use,1,35 increased antibiotic resistance35 and unnecessary health care costs.19,36

Penicillin
The most common drug allergic reaction to penicillin is a cutaneous reaction — either macular, morbilliform or urticarial.1 Penicillin undergoes spontaneous conversion to reactive intermediates under physiologic conditions. Most degrade to the penicilloyl moiety (major determinant) and the remainder degrade into several other moieties (minor determinants).2 Skin testing with penicillin reagents has a high negative predictive value in the diagnosis of IgE-mediated penicillin allergy, with an oral challenge by an allergist as a confirmatory step if negative.

Recent studies have shown that as many as 98% of patients with a history of penicillin allergy are found to have negative penicillin skin tests and will tolerate penicillins.26 Re-evaluation is suggested even in those with confirmed (based on skin testing or oral challenge) penicillin allergy. An evaluation conducted in a pediatric emergency department that involved 100 children with a history of penicillin allergy found that 100% (95% CI 96.4%–100%) of these children with low-risk symptoms had negative results for allergy testing (skin testing and drug provocation test).33 Evaluation is especially useful if the reaction occurred more than 5 to 10 years ago, because there is a high rate of resolution for penicillin allergy.38,40,41 For example, a retrospective study involving 740 patients with a history of β-lactam allergy found that 93% of these patients had a positive result for skin testing if the reaction was in the past year; this decreased to 22% of patients with a positive test result if they were evaluated 10 or more years after their clinical reaction.38

Amoxicillin and cephalosporins
Amoxicillin and ampicillin are associated with a delayed (type 4) maculopapular rash in 5%–10% of patients, and in 100% of patients with co-existing Epstein–Barr virus.4 These amoxicillin reactions are not life-threatening and not an absolute contraindication to future amoxicillin or ampicillin use.

Although cephalosporins can also cause acute allergic reactions, overall the reaction rate is about 10-fold lower than for penicillin.1 Cross reactivity between cephalosporins and penicillin is thought to be very low.41 The Canadian Pediatric Society’s guideline on otitis media notes that children with a history of reactivity to penicillin or amoxicillin can safely be prescribed second- or third-generation cephalosporins as long as the previous reaction was not life-threatening.42 A 2016 review also reported that avoidance of cephalosporins in patients with amoxicillin or penicillin allergy could result in substantial morbidity, and concluded that there was “ample evidence to allow the safe use of cephalosporins in patients with isolated confirmed penicillin or amoxicillin allergy.”43

Amoxicillin and cephalosporins contain “R” side chains in addition to the β-lactam ring, which may be allergenic. Sensitization to the β-lactam portion of penicillin would result in sensitization to all β-lactam antibiotics; in contrast, sensitization to the R side chain would lead to tolerance of most β-lactam antibiotics (except those with a common side chain). For example, amoxicillin shares an identical R side chain with cefprozil; ampicillin with cefaclor and cephalaxin; and ceftriaxone with cefotaxime. For cephalosporins, if an acute allergic reaction does occur, it is often directed at the R-group side chain instead of the common β-lactam ring.8

Although skin testing has not been validated for β-lactams other than penicillin, it can still have some utility if there is a history consistent with an IgE-mediated reaction — patients with negative results for penicillin skin tests can safely receive β-lactam antibiotics, and patients with confirmed penicillin allergy usually tolerate carbapenem and aztreonam.44 Skin testing reagents have been developed for amoxicillin and cephalosporins; however, their negative predictive value has not been validated.2 If patients with a history of a reaction to amoxicillin have negative results for skin testing to the penicillin reagents, an oral challenge to amoxicillin is often considered by an allergist to rule out definitively IgE-mediated allergy. A recent Canadian cohort study also suggested that a graded oral challenge alone in an allergy clinic may be an effective diagnostic test for amoxicillin allergy in children finding that among 818 children with suspected amoxicillin allergy, a graded oral challenge was both safe and accurate. Almost all children (94.1%) tolerated the oral challenge, and the reactions when present were mild.45

The approach to administration of cephalosporins or penicillin in the context of an allergic reaction is outlined in Table 4, as suggested by the Joint Task Force on Practice Parameters.1

Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are used commonly in North America and can cause different reactions that are either allergic in nature or, more commonly, nonimmune (and related to cyclooxygenase-1 [COX-1] inhibition) (Table 5). A retrospective review involving all adult patients in an American health care system who were prescribed NSAIDs over an eight-year period reported that 17% of those patients had an adverse drug reaction, of which 18.3% were allergic.46 The common types of NSAID-induced reactions are NSAID-exacerbated respiratory disease, single–NSAID-induced anaphylaxis or urticaria/angioedema (which could be NSAID-exacerbated, NSAID-induced or single–NSAID-induced) (Table 4).47 Delayed reactions, such as Stevens–Johnson syndrome, delayed maculopapular rash or fixed drug eruptions, are also possible with NSAIDs.

Nonsteroidal anti-inflammatory drug–exacerbated respiratory disease presents with upper and lower respiratory symptoms within three hours after NSAID ingestion, mostly in adult patients with a history of underlying asthma and rhinosinusitis.47 It is related to COX-1 inhibition and is diagnosed with an oral provocation test. Treatment is avoidance of COX-1 inhibitors (COX-2 inhibitors are usually safe); if asthma or rhinosinusitis is refractory to medical and surgical therapy, ASA induction of tolerance followed by ASA therapy can be considered as well.2

Patients who present with cutaneous symptoms after NSAID exposure may have one of three conditions: NSAID-exacerbated cutaneous disease, NSAID-induced urticaria/angioedema or
All of these conditions present with angioedema/urticaria; however, the time frame differs slightly: NSAID-exacerbated cutaneous disease and NSAID-induced urticaria/angioedema can present up to several hours after NSAID ingestion (although presentation is often immediate), and single-NSAID-induced urticaria/angioedema or anaphylaxis presentation is uniformly immediate. In addition, NSAID-exacerbated cutaneous disease presents in patients with a history of chronic urticaria, and the pathophysiology differs between these conditions (Table 4). Distinguishing between these conditions by drug provocation testing (to both the implicated NSAID and a chemically unrelated NSAID) is beneficial as a means of differentiating the conditions and predicting the extent of necessary NSAID avoidance according to a 2013 review. For NSAID-exacerbated cutaneous disease and NSAID-induced urticaria/angioedema, all COX-1 inhibitors should be avoided (COX-2 inhibitors are usually safe). For single-NSAID–induced urticaria/angioedema or anaphylaxis, only the implicated NSAID and chemically related NSAIDs must be avoided. For all of these conditions, COX-2 inhibitors are largely well tolerated.

**Table 4: Administration of penicillin or cephalosporins in the context of a previous reaction**

| Drug administered | Reaction to cephalosporin | Reaction to penicillin |
|-------------------|--------------------------|-----------------------|
| Cephalosporin     | 1. Graded challenge to cephalosporin with different side chain or 2. Skin test to different cephalosporin  • If result is negative, give via graded challenge  • If result is positive, avoid or desensitize | 1. Penicillin skin testing  • Give cephalosporin if result is negative  • Avoid cephalosporin, give cephalosporin via graded challenge or desensitize to cephalosporin if result is positive or 2. Cephalosporin skin testing  • Give cephalosporin via graded challenge if result is negative  • Avoid or desensitize to cephalosporin if results is positive |
| Penicillin        | 1. Graded challenge to penicillin or 2. Skin test to penicillin  • If result is negative, give penicillin  • If result is positive, give alternate drug or desensitize to penicillin | Penicillin skin test  • If result is positive, avoid penicillin or desensitize  • If result is negative, give penicillin via challenge |

**Table 5: Allergic reactions induced by nonsteroidal anti-inflammatory drugs**

| Pathophysiology                  | Reaction type | Underlying condition | Symptoms                  |
|----------------------------------|---------------|----------------------|--------------------------|
| COX-1 inhibition (nonimmune)     | NERD          | Asthma, rhinitis, sinusitis, polyps | Upper and lower respiratory |
| NECD                             | Chronic urticaria |                       | Cutaneous                |
| NIUA                             | –             |                       | Cutaneous                |
| IgE-mediated (immune-mediated)   | SNIUAA        | –                    | Cutaneous or anaphylaxis |

Note: COX-1 = cyclooxygenase-1, IgE = immunoglobulin E, NECD = NSAID-exacerbated cutaneous disease, NERD = NSAID-exacerbated respiratory disease, NIUA = NSAID-induced urticaria/angioedema, NSAID = nonsteroidal anti-inflammatory drug, SNIUAA = single-NSAID-induced urticaria/angioedema or anaphylaxis.

**Conclusion**

Although adverse drug reactions are common, allergic reactions are uncommon. Cutaneous manifestations are the most common clinical manifestation of an allergic drug reaction. Diagnosis largely relies on medical history, because there are few standardized tests in the diagnosis of drug allergy, with the exception of skin testing for penicillin. However, evaluation of patients labelled as allergic remains an important public health goal because mislabelling can have health consequences, such as increased morbidity and public health costs.

**References**

1. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. *Ann Allergy Asthma Immunol* 2010;105:259-73.

2. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA* 1995;274:29-34.

3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998;279:1200-5.

4. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. *Curr Opin Allergy Clin Immunol* 2005;5:309-16.
5. Adverse reaction and medical device problem reporting. Ottawa: Health Canada (modified 2017 Oct. 10). Available: www.canada.ca/en/health-canada/services/drugs-health-products/medeefect-canada/adverse-reaction-reporting.html (accessed 2018 Feb. 15).

6. Adverse drug reaction-related hospitalizations among seniors, 2006 to 2011. Ottawa: Canadian Institute for Health Information (CIHI); March 2013. Available: https://secure.cihi.ca/free_products/Hospitalizations%20for%20ADR_EN-web.pdf (accessed 2018 Feb. 15).

Chih-Min Torres, Alba Romano, Robert J. Adkinson, Thomas F. Bieber, Joseph R. Bruno, Kamal A. Bui, Margaret A. Cargill, Charles D. Chiang, Resa Z. Cohen, Yi-Chun Diao, John M. DiBisceglie, Adam M. Dickey, Mohamad H. Dib, Carol E. DiLillo, Michael S. Dlugos, William W. Dooley, John R. Dvorak, Randi A. Edelson, Christopher A. Egan, Imran M. Elobeid, Christine L. Englund, Patricia S. Erslev, George J. Fireman, Oded Gonen, Reem M. Ghanayem, Paul A. Glick, John M. Goldblatt, Michael J. Goldstein, Peter M. Goldsmith, Michael J. Gorelick, Robert W. Green, Michael A. Greer, Dwight A. Grinnell, Joseph T. Gruenwald, Robert C. Gundersen, John E. Haas, John H. Hamman, David W. Hargarten, Brian M. Harrison, Steven M. Hartman, Andrew E. Hay, Scott L. Hendren, Richard S. Henry, Joseph A. Hensinger, Michael J. Herr, Robert D. Hiebert, Michael T. Hlavacek, Michael J. Hopp, Tim C. Howden, Scott A. Houck, Alan M. Huefner, William H. Huggins, Robert A. Hume, Feiling Hwang, Eunice W. Hwang, Anneliese M. Hurst, Andrew J. Hyland, Donna S. Ioffe, Stephen J. Isern, Richard D. Jaro, Michael C. Jee, Craig R. Jones, Kenneth S. Jones, Angela D. Kahl, E. Erin Kelleher, Ramona L. Kellner, Jason M. Kelly, Carla M. Kennamer, William W. Kersten, Karen A. Kieffer, Geoffrey G. Kim, C. Lisa Kim, Robert C. Kimball, Robert E. Kirschenheuter, John E. Kolasinski, John R. Koepsell, Michael K. Kohr, Michael R. Kohrman, Marissa Kompass, Marc J. Konstan, John E. Konstan, Thomas J. Kosinski, Maria Loukas, Thomas A. Kurtin, Andrew S. Kuziel, L. Chadrick R. Lake, Shu-Min Lam, T. Ross Lawrence, Michael C. Laviolette, software development by University of British Columbia, Vancouver, BC; Department of Internal Medicine (Khan), Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.

Correspondence to: Elissa Abrams, elissa.abrams@gmail.com